Literature DB >> 16720756

Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents.

Xavier de Leval1, Thibaut Dassesse, Jean-Michel Dogné, David Waltregny, Akeila Bellahcène, Valérie Benoit, Bernard Pirotte, Vincent Castronovo.   

Abstract

Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A(2) (TXA(2)) inhibitors derived from torasemide, a marketed loop diuretic with TXA(2) antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay. All drugs tested exhibited a marked affinity toward human platelet TXA(2) receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA(2) receptor agonist, and inhibited platelet TXA(2) synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. These dual TXA(2) inhibitors dose dependently inhibited endothelial cell migration in chemotaxis assays using vascular endothelial growth factor (VEGF) as a chemoattractant but failed to affect cell adhesion and viability. The highest rates of cell migration inhibition were obtained with original compounds BM-567 and BM-573 (50.3 and 59.4% inhibition, respectively) when used at the final concentration of 10 microM. In addition, pretreatment of endothelial cells with these two drugs significantly prevented U-46,619-induced intracellular Ca(2+) pool mobilization, thus suggesting a mechanistic link between inhibition of the TXA(2) pathway and reduced endothelial cell migration. Treatment of rat aortic explants with U-46,619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F(2)) significantly enhanced vessel sprouting whereas aortic rings treated with some of the compounds, including BM-567 (N-n-pentyl-N'-[2-(cyclohexylamino)-5-nitrobenzenesulfonyl]urea) and BM-573 (N-tert-butyl-N'-[5-nitro-2-p-toluylaminobenzenesulfonyl]urea), showed a significant decrease in vessel sprouting, which was not reversed by the addition of VEGF. These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720756     DOI: 10.1124/jpet.106.101188

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

Review 2.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.

Authors:  Run-Yue Huang; Shan-Shan Li; Hui-Zhen Guo; Yu Huang; Xian Zhang; Ming-Yue Li; George Gong Chen; Xing Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-03       Impact factor: 4.553

4.  Synthesis of novel aryl(heteroaryl)sulfonyl ureas of possible biological interest.

Authors:  Franciszek Saczewski; Anna Kuchnio; Monika Samsel; Marta Łobocka; Agnieszka Kiedrowska; Karolina Lisewska; Jarosław Saczewski; Maria Gdaniec; Patrick J Bednarski
Journal:  Molecules       Date:  2010-02-26       Impact factor: 4.411

Review 5.  The Role and Regulation of Thromboxane A2 Signaling in Cancer-Trojan Horses and Misdirection.

Authors:  Anthony W Ashton; Yunjia Zhang; Rosanna Cazzolli; Kenneth V Honn
Journal:  Molecules       Date:  2022-09-22       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.